<DOC>
	<DOCNO>NCT00620087</DOCNO>
	<brief_summary>We aim determine Molecular Breast Imaging ( new nuclear medicine technique develop Mayo ) identify malignant breast lesion woman atypical ductal hyperplasia , atypical lobular hyperplasia , lobular carcinoma situ .</brief_summary>
	<brief_title>Molecular Breast Imaging Women With Atypia LCIS</brief_title>
	<detailed_description>Management atypical ductal hyperplasia ( ADH ) , atypical lobular hyperplasia ( ALH ) , lobular carcinoma situ ( LCIS ) diagnose breast needle core needle biopsy controversial . Current practice recommend excisional biopsy rule malignant lesion , report half case series . No consistent clinical , pathologic , radiologic factor identify select patient require surgical excision . This due , part , overlap mammographic feature benign malignant lesion . Furthermore , reliance mammography surveillance high-risk patient problematic . This highlight need complementary imaging modality improve radiologic distinction benign malignant tumor improve post-biopsy surveillance . We evaluate new semiconductor-based gamma camera call Molecular Breast Imaging ( MBI ) improve resolution factor 2-3 compare conventional gamma camera , , unlike mammography , affect breast density . Preliminary clinical study ( IRB 0-1761-01 ) ) show scintimammography ( SM ) use Tc-99m sestamibi CZT camera ( CZT-SM ) high sensitivity specificity evaluation small ( 5-10 mm ) lesion see mammography . We hypothesize MBI reliably distinguish lesion require excisional biopsy lesion . A secondary aim compare role MBI mammography post-biopsy surveillance . We aim enroll 50 Mayo patient receive diagnosis ADH , ALH , LCIS core biopsy , yet undergone excisional biopsy , consent undergo MBI breast . For image discordance mammographic finding , ultrasound use determine additional abnormality warrant excision . Using pathologic correlation , determine : 1 ) If residual focus ADH , ALH , LCIS visible MBI image ; 2 ) If MBI image reliably predict contiguous separate focus malignant lesion either breast .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<criteria>Inclusion Criteria Surveillance Arm : Diagnosis biopsyprove ADH , ALH , LCIS within past 5 year base core needle biopsy and/or excisional biopsy confirm Mayo pathologist . Inclusion Criteria Diagnostic Arm : Recent core needle biopsy breast demonstrate ADH , ALH , LCIS confirm Mayo pathologist . They unable understand sign consent form They pregnant lactate They physically unable sit upright still 40 minute They younger 18 year age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Atypical lobular hyperplasia</keyword>
	<keyword>Atypical ductal hyperplasia</keyword>
	<keyword>Lobular carcinoma situ</keyword>
	<keyword>Molecular Breast Imaging</keyword>
</DOC>